Shanghai team develops first drug candidate for erectile dysfunction

A novel phosphodiesterase type 5 (PDE5) inhibitor TPN729, developed by Shanghai Institute of Materia Medica, is entering phase I of clinical trials after excellent preclinical results.

CAS news release, July 22, 2013

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny